Acknowledgement
This work was supported by the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT) (NRF-2020R1F1A1066320).
References
- Ashley EA. The precision medicine initiative: a new national effort. JAMA 2015;313:2119-2120. https://doi.org/10.1001/jama.2015.3595
- Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793-795. https://doi.org/10.1056/NEJMp1500523
- Riddick G, Song H, Ahn S, Walling J, Borges-Rivera D, Zhang W, et al. Predicting in vitro drug sensitivity using Random Forests. Bioinformatics 2011;27:220-224. https://doi.org/10.1093/bioinformatics/btq628
- Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol 2014;15:R47. https://doi.org/10.1186/gb-2014-15-3-r47
- Zhang N, Wang H, Fang Y, Wang J, Zheng X, Liu XS. Predicting anticancer drug responses using a dual-layer integrated cell linedrug network model. PLoS Comput Biol 2015;11:e1004498. https://doi.org/10.1371/journal.pcbi.1004498
- Wei D, Liu C, Zheng X, Li Y. Comprehensive anticancer drug response prediction based on a simple cell line-drug complex network model. BMC Bioinformatics 2019;20:44. https://doi.org/10.1186/s12859-019-2608-9
- Wang L, Li X, Zhang L, Gao Q. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization. BMC Cancer 2017;17:513. https://doi.org/10.1186/s12885-017-3500-5
- Shivakumar P, Krauthammer M. Structural similarity assessment for drug sensitivity prediction in cancer. BMC Bioinformatics 2009;10 Suppl 9:S17. https://doi.org/10.1186/1471-2105-10-S9-S17
- Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013;41:D955-D961. https://doi.org/10.1093/nar/gks1111
- De Niz C, Rahman R, Zhao X, Pal R. Algorithms for drug sensitivity prediction. Algorithms 2016;9:77. https://doi.org/10.3390/a9040077
- Benesty J, Chen J, Huang Y, Cohen I. Noise Reduction in Speech Processing. Vol. 2. Berlin: Springer, 2009. pp. 37-40.
- Kim JH, Yim SH, Jeong YB, Jung SH, Xu HD, Shin SH, et al. Comparison of normalization methods for defining copy number variation using whole-genome SNP genotyping data. Genomics Inform 2008;6:231-234. https://doi.org/10.5808/GI.2008.6.4.231
- Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc B 2005;67:301-320. https://doi.org/10.1111/j.1467-9868.2005.00503.x
- Basak D, Pal S, Ch D, Patranabis R. Support vector regression. Neural Inf Process Lett Rev 2007;11:203-224.
- Chen T, Guestrin C. Xgboost: a scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, 2016 Aug 13-17, San Francisco, CA, USA. New York: ACM, 2016. pp. 785-794.
- Bisong E. Building Machine Learning and Deep Learning Mdels on Google Cloud Platform: A Comprehensive Guide for Beginners. Berkeley, CA: Apress, 2019. pp. 151-165.
- Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 2019;10:1523. https://doi.org/10.1038/s41467-019-09234-6
- Zhang H, Liu J, Fu X, Yang A. Identification of key genes and pathways in tongue squamous cell carcinoma using bioinformatics analysis. Med Sci Monit 2017;23:5924-5932. https://doi.org/10.12659/MSM.905035
- Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6:2209-2219. https://doi.org/10.1158/1535-7163.MCT-07-0231
- Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, et al. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18) (q32;q21). Leukemia 2011;25:856-867. https://doi.org/10.1038/leu.2011.28
- Hadley KE, Hendricks DT. Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG. BMC Cancer 2014;14:334. https://doi.org/10.1186/1471-2407-14-334
- Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G, et al. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res 2009;69:6241-6248. https://doi.org/10.1158/0008-5472.CAN-09-0337
- Liu M, Liu H, Chen J. Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review). Oncol Rep 2018;39:901-911.